Client News

OKYO Pharma Limited: Grant of options – Director and PDMR dealings
Home / Client News / OKYO Pharma Limited: Grant of options – Director and PDMR dealings

London 1 February, 2022 – OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, announces that the board of directors of the Company (the “Board” or “Directors”), acting on a recommendation of the Remuneration Committee with Mr Brancaccio and Mr Denoyer absenting themselves on grounds of interest, has awarded the following options on 31 January 2022.

https://www.londonstockexchange.com/news-article/OKYO/director-pdmr-shareholding/15309674

OPEN AN ACCOUNT

If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.

CLIENT AREA

Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

Share This